WO1994006345A2 - Immunosorbent for use in the diagnosis of neuro-psychological disorders, and use thereof - Google Patents

Immunosorbent for use in the diagnosis of neuro-psychological disorders, and use thereof Download PDF

Info

Publication number
WO1994006345A2
WO1994006345A2 PCT/RU1993/000131 RU9300131W WO9406345A2 WO 1994006345 A2 WO1994006345 A2 WO 1994006345A2 RU 9300131 W RU9300131 W RU 9300131W WO 9406345 A2 WO9406345 A2 WO 9406345A2
Authority
WO
WIPO (PCT)
Prior art keywords
neuro
immunosorbent
diagnosis
psychological disorders
fragment
Prior art date
Application number
PCT/RU1993/000131
Other languages
English (en)
French (fr)
Other versions
WO1994006345A3 (en
Inventor
Galina Alexandrovna Isykenova
Original Assignee
Dambinova Svetlana Alexandrovn
Galina Alexandrovna Isykenova
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dambinova Svetlana Alexandrovn, Galina Alexandrovna Isykenova filed Critical Dambinova Svetlana Alexandrovn
Priority to JP6508000A priority Critical patent/JP2782695B2/ja
Publication of WO1994006345A2 publication Critical patent/WO1994006345A2/ru
Publication of WO1994006345A3 publication Critical patent/WO1994006345A3/ru

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Peptides Or Proteins (AREA)
PCT/RU1993/000131 1992-09-11 1993-06-11 Immunosorbent for use in the diagnosis of neuro-psychological disorders, and use thereof WO1994006345A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP6508000A JP2782695B2 (ja) 1992-09-11 1993-06-11 神経症および精神病の診断用免疫吸着剤およびその実際的用途

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SU9200173 1992-09-11

Publications (2)

Publication Number Publication Date
WO1994006345A2 true WO1994006345A2 (en) 1994-03-31
WO1994006345A3 WO1994006345A3 (en) 1995-01-19

Family

ID=21617817

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/RU1993/000131 WO1994006345A2 (en) 1992-09-11 1993-06-11 Immunosorbent for use in the diagnosis of neuro-psychological disorders, and use thereof

Country Status (2)

Country Link
JP (1) JP2782695B2 (ru)
WO (1) WO1994006345A2 (ru)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2782631A1 (fr) 1998-08-25 2000-03-03 Patrick Metais Dispositif de prelevement de cellules du cerveau humain en vue d'un diagnostic post-mortem de maladie d'alzheimer
US7820398B2 (en) 2003-11-06 2010-10-26 Grace Laboratories Inc. Immunosorbent blood tests for assessing paroxysmal cerebral discharges

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU773265B2 (en) * 1998-11-05 2004-05-20 Regents Of The University Of Michigan, The S100 proteins and autoantibodies as serum markers for cancer

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0123901A2 (en) * 1983-03-31 1984-11-07 Byk-Sangtec Diagnostica GmbH & Co. KG Procedure for the irreversible binding of proteins onto polystyrene surfaces with retention of their biological activity, polystyrene surfaces obtained by this procedure, and their use
US4666829A (en) * 1985-05-15 1987-05-19 University Of California Polypeptide marker for Alzheimer's disease and its use for diagnosis
EP0233385A1 (en) * 1986-01-13 1987-08-26 De Staat Der Nederlanden Vertegenwoordigd Door De Minister Van Welzijn, Volksgezondheid En Cultuur Method for detecting a member of a ligand-receptor pair, method for the preparation of a carrier to which this member is bonded and analysis equipment therefor
EP0249877A2 (de) * 1986-06-20 1987-12-23 Roche Diagnostics GmbH Verfahren zur Herstellung eines immunreaktiven Trägermaterials für die heterogene immunologische Analyse
EP0253464A1 (en) * 1986-03-21 1988-01-20 Hybritech Incorporated Methods for providing internal references for use in analyte receptor assays
EP0253578A2 (en) * 1986-07-15 1988-01-20 Hybritech Incorporated A solid phase system incorporating tetrazolium salts for use in ligand-receptor assays
WO1989001159A1 (en) * 1987-07-27 1989-02-09 Commonwealth Scientific And Industrial Research Or Receptor membranes
WO1989008259A1 (en) * 1988-02-29 1989-09-08 Boehringer Mannheim Gmbh Process for producing a solid phase matrix
US4910152A (en) * 1985-01-31 1990-03-20 Meyers Vera K Method for binding opioid receptors

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0123901A2 (en) * 1983-03-31 1984-11-07 Byk-Sangtec Diagnostica GmbH & Co. KG Procedure for the irreversible binding of proteins onto polystyrene surfaces with retention of their biological activity, polystyrene surfaces obtained by this procedure, and their use
US4910152A (en) * 1985-01-31 1990-03-20 Meyers Vera K Method for binding opioid receptors
US4666829A (en) * 1985-05-15 1987-05-19 University Of California Polypeptide marker for Alzheimer's disease and its use for diagnosis
EP0233385A1 (en) * 1986-01-13 1987-08-26 De Staat Der Nederlanden Vertegenwoordigd Door De Minister Van Welzijn, Volksgezondheid En Cultuur Method for detecting a member of a ligand-receptor pair, method for the preparation of a carrier to which this member is bonded and analysis equipment therefor
EP0253464A1 (en) * 1986-03-21 1988-01-20 Hybritech Incorporated Methods for providing internal references for use in analyte receptor assays
EP0249877A2 (de) * 1986-06-20 1987-12-23 Roche Diagnostics GmbH Verfahren zur Herstellung eines immunreaktiven Trägermaterials für die heterogene immunologische Analyse
EP0253578A2 (en) * 1986-07-15 1988-01-20 Hybritech Incorporated A solid phase system incorporating tetrazolium salts for use in ligand-receptor assays
WO1989001159A1 (en) * 1987-07-27 1989-02-09 Commonwealth Scientific And Industrial Research Or Receptor membranes
WO1989008259A1 (en) * 1988-02-29 1989-09-08 Boehringer Mannheim Gmbh Process for producing a solid phase matrix

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2782631A1 (fr) 1998-08-25 2000-03-03 Patrick Metais Dispositif de prelevement de cellules du cerveau humain en vue d'un diagnostic post-mortem de maladie d'alzheimer
US7820398B2 (en) 2003-11-06 2010-10-26 Grace Laboratories Inc. Immunosorbent blood tests for assessing paroxysmal cerebral discharges

Also Published As

Publication number Publication date
JPH07506049A (ja) 1995-07-06
WO1994006345A3 (en) 1995-01-19
JP2782695B2 (ja) 1998-08-06

Similar Documents

Publication Publication Date Title
Levitt et al. Mouse pre-B cells synthesize and secrete μ heavy chains but not light chains
Harding et al. Quantitation of antigen-presenting cell MHC class II/peptide complexes necessary for T-cell stimulation
Korman et al. Drug-induced pemphigus: autoantibodies directed against the pemphigus antigen complexes are present in penicillamine and captopril-induced pemphigus
KR910002897A (ko) 에리트로포이에틴(epo)펩타이드 및 이에 대한 항체
CA2025597A1 (en) Vaccine against lyme disease
EP0440619A4 (en) ANTIBODIES ACTING ON A PEPTIDE OF THE A4 SEQUENCE AMYLOID.
EP0994728A4 (en) SPECIFIC, RECOMBINANT ANTIBODIES FOR THE TERMINI OF BETA AMYLOIDS, CODING DNA FOR THEM AND METHOD FOR THEIR USE
GB8806339D0 (en) Monoclonal antibodies
EP0444856A3 (en) Diagnostic assay for alzheimer's disease
EP0674661A4 (en) TITRATION AND TREATMENT FOR DEMYELINIZING DISEASES SUCH AS MULTIPLE SCLEROSIS.
Bennet et al. The production and characterization of murine monoclonal antibodies to a DNA receptor on human leukocytes.
JPS6312297A (ja) ヒトインタ−ロイキン−２−リセプタ−を認識するモノクロ−ナル抗体
GR3025630T3 (en) Monoclonal antibody against human IgE
Deshmukh et al. Immune responses to small nuclear ribonucleoproteins: antigen-dependent distinct B cell epitope spreading patterns in mice immunized with recombinant polypeptides of small nuclear ribonucleoproteins
WO1994006345A2 (en) Immunosorbent for use in the diagnosis of neuro-psychological disorders, and use thereof
Faissner Monoclonal antibody detects carbohydrate microheterogeneity on the murine cell adhesion molecule L1
Roch et al. Serological evidences for a membrane structure related to human β2‐microglobulin expressed by certain earthworm leukocytes
PT1181366E (pt) Proteínas receptoras de mamífero; reagentes e métodos relacionados
McMillan Clinical role of antiplatelet antibody assays
UY23374A1 (es) Procedimiento para la preparacion de anticuerpos del receptor ige
DE69216600T2 (de) Synthetisches CDw52(CAMPATH-1) Peptidantigen
AU5809290A (en) Monoclonal antibodies involved in alzheimer's disease, hybridomas secreting these monoclonal antibodies, antigen recognized by these antibodies, and their application
Davis et al. Ferritin-antibody localization of erythrocyte antigenic sites in immunohemolytic anemias
Fudenberg Compleat immunology: science or septophrenia?
Scharff et al. Hybridomas as a source of antibodies

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): JP US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

ENP Entry into the national phase in:

Ref country code: US

Ref document number: 1994 244706

Date of ref document: 19940603

Kind code of ref document: A

Format of ref document f/p: F

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): JP US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

122 Ep: pct application non-entry in european phase